Assessment Status |
NCPE assessment ongoing |
HTA ID |
21066 |
Drug |
Osimertinib |
Brand |
Tagrisso® |
Indication |
or adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer whose tumour has epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. |
Rapid review commissioned |
20/12/2021 |
Rapid review completed |
13/01/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
31/01/2022 |
Pre-submission consultation with Applicant |
15/03/2022 |
Full submission received from Applicant |
16/08/2022 |
Preliminary review sent to Applicant |
27/01/2022 |
NCPE assessment re-commenced |
13/03/2023 |